Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2017			10,000	9,484,000
Beginning Balance at Dec. 31, 2017	$ 50,189	$ 50,507	$ 0	$ 9	$ 433,044	$ (28)	$ (381,810)	$ (708)	$ (318)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(12,611)	(12,609)					(12,609)		(2)
Unrealized gain on marketable securities	(1)	(1)				(1)
Share-based compensation (in shares)				127,000
Share-based compensation	1,879	1,879		$ 1	1,878
Net proceeds from issuance of common stock (in shares)				165,000
Net proceeds from issuance of common stock	998	998			998
Proceeds from option exercises (in shares)				77,000
Proceeds from option exercises	355	355			355
Change in ownership in subsidiary	0	(48)			(48)				48
Ending Balance (shares) at Sep. 30, 2018			10,000	9,853,000
Ending Balance at Sep. 30, 2018	40,809	41,081	$ 0	$ 10	436,227	(29)	(394,419)	(708)	(272)
Beginning Balance (shares) at Jun. 30, 2018			10,000	9,736,000
Beginning Balance at Jun. 30, 2018	43,468	43,741	$ 0	$ 10	435,339	(31)	(390,869)	(708)	(273)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,549)	(3,550)					(3,550)		1
Unrealized gain on marketable securities	2	2				2
Share-based compensation (in shares)				0
Share-based compensation	165	165			165
Net proceeds from issuance of common stock (in shares)				115,000
Net proceeds from issuance of common stock	710	710			710
Proceeds from option exercises (in shares)				2,000
Proceeds from option exercises	13	13			13
Ending Balance (shares) at Sep. 30, 2018			10,000	9,853,000
Ending Balance at Sep. 30, 2018	40,809	41,081	$ 0	$ 10	436,227	(29)	(394,419)	(708)	(272)
Beginning Balance (shares) at Dec. 31, 2018			10,000	9,866,000
Beginning Balance at Dec. 31, 2018	37,454	37,726	$ 0	$ 10	436,433	(32)	(397,977)	(708)	(272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Adoption of accounting standard	(62)	(62)					(62)
Net loss	(14,399)	(14,405)					(14,405)		6
Unrealized gain on marketable securities	34	34				34
Share-based compensation (in shares)				94,000
Share-based compensation	917	917			917
Net proceeds from issuance of common stock (in shares)				451,000
Net proceeds from issuance of common stock	1,038	1,038			1,038
Ending Balance (shares) at Sep. 30, 2019			10,000	10,411,000
Ending Balance at Sep. 30, 2019	24,982	25,248	$ 0	$ 10	438,388	2	(412,444)	(708)	(266)
Beginning Balance (shares) at Jun. 30, 2019			10,000	10,413,000
Beginning Balance at Jun. 30, 2019	29,622	29,889	$ 0	$ 10	438,133	0	(407,546)	(708)	(267)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,897)	(4,898)					(4,898)		1
Unrealized gain on marketable securities	2	2				2
Share-based compensation (in shares)				(2,000)
Share-based compensation	254	254			254
Net proceeds from issuance of common stock (in shares)				0
Net proceeds from issuance of common stock	1	1			1
Ending Balance (shares) at Sep. 30, 2019			10,000	10,411,000
Ending Balance at Sep. 30, 2019	$ 24,982	$ 25,248	$ 0	$ 10	$ 438,388	$ 2	$ (412,444)	$ (708)	$ (266)